InSightech will release its new ExAblate One and ExAblate OR products at the upcoming meeting of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE).

InSightech said the ExAblate One and OR products employ focused ultrasound to conduct non-invasive interventional treatment and research on uterine fibroids, adenomyosis breast and prostate cancers and other women’s health indications.

The ExAblate One identifies, heats and destroys targeted bone tissue using MR guidance. The new ExAblate One provides real-time temperature readings on the treated tissue and can be used to treat large and vascular fibroids, said Trat Carmel, Israel-based InSightech.